国产吉西他滨或长春瑞滨联合顺铂治疗进展期非小细胞肺癌的临床观察

目的:观察国产吉西他滨联合顺铂(GP组)与长春瑞滨联合顺铂(NP组)治疗进展期非小细胞肺癌的疗效及毒副反应。方法:经病理组织学或细胞学证实的不能手术的80例非小细胞肺癌患者,随机分为两组各40例,以吉西他滨1200mg/m2静滴,第1,8天;长春瑞滨25mg/m2静滴,第1,8天,分别联合顺铂80mg/m2第1天或分2~3天静滴,21天为1周期,3周期以上评价疗效。结果:两组的有效率分别为47.5%(19/40)、45.0%(18/40),无显著性差异;中位疾病进展时间分别为4.9个月和4.1个月,组间有显著性差异(P<0.05);1年生存率GP组为42.5%(17/40),NP组为40.0%(16/40),组间无显著性差异。GP组III~IV度血小板减少高于NP组,而III~IV度白细胞减少及脱发、静脉炎明显低于NP组。结论:两种方案治疗晚期NSCLC均安全、有效,在有效率、中位生存期及1年生存率方面均较接近,毒副反应均可耐受,但中位疾病进展时间GP组稍有优势。

The clinical observation of gemcitabine or vinorelbine combined with cisplatin in the treatment of advanced non -small cell lung cancer

Objective:To observe the efficacy,toxicity and side effects of gemcitable or vinorelbine cominld with cisplation in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods: Total of 80 patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into two groups randomly, 40 in each group . Group gemcitabine with 40 patients received gemcitabine 1200 mg/m2 on d1,8 and cisplatin 80mg/m2 on d1,d3; group vinorelbine received vinorelbine 25 mg/m2 on d1,8 and cisplatin 80 mg/m2 on d1,d3. Both regiments had 21 days for each cycle, three weeks repeated and the efficacy was observed after 3 periods. Results: The effective rates of group gemcitabine and vinorelbine were 47.5% (19/40) and 45.0%(18/40) respectively, there was no significant difference (P>0.05) between two groups. The median ailment development time were 4.9 and 4.1 months for group gemcitabine and vinorelbine ,respectively and there was sfafastic difference (P<0.05). The 1-year survival rates were 42.5% for group gemcitabine and 40.0% for group vinorelbine, no significant difference (P>0.05).Thrombocytopenia with group gemcitabine was higher than that of group vinorelbine but the leucopenian and alopecia and phlebitis in group gemcitabine were apparently lower than that in group vinorelbine. Conclusion: There was no significant difference between group gemcitabine and vinorelbine on efficacy ,median survival time and 1-year survival rate ,but there was a little advantage in group gemcitabine on median ailment development time. Both regimens are effective and well tolerated for patients with advanced non-small cell lung cancer.